Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? (original) (raw)

• Hahn, W. C. et al. Creation of human tumour cells with defined genetic elements. Nature 400, 464–468 (1999).
  CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Aaltonen, L. A. et al. Clues to the pathogenesis of familial colorectal cancer. Science 260, 812–816 (1993).
  CAS PubMed Google Scholar
• Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159–170 (1996).
  CAS PubMed Google Scholar
• Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761–763 (1997).
  Article CAS PubMed Google Scholar
• Jones, P. A. & Laird, P. W. Cancer epigenetics comes of age. Nature Genet. 21, 163–167 (1999).
  CAS PubMed Google Scholar
• Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143–153 (2004).
  CAS Google Scholar
• Herman, J. G. & Baylin, S. B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054 (2003).
  CAS PubMed Google Scholar
• Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415–428 (2002). Highlights how patterns of DNA methylation and chromatin structure are profoundly altered in neoplasia.
  CAS PubMed Google Scholar
• Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262–1266 (2005).
  CAS PubMed Google Scholar
• Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391–400 (2005).
  CAS PubMed Google Scholar
• Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672–2681 (2002).
  CAS PubMed PubMed Central Google Scholar
• Lachner, M., O'Sullivan, R. J. & Jenuwein, T. An epigenetic road map for histone lysine methylation. J. Cell Sci. 116, 2117–2124 (2003). Reviews the known complexity of histone modifications including the methylation, acetylation and phosphorylation of histone residues.
  CAS PubMed Google Scholar
• Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).
  CAS PubMed Google Scholar
• Fischle, W., Wang, Y. & Allis, C. D. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15, 172–183 (2003).
  CAS PubMed Google Scholar
• Hake, S. B., Xiao, A. & Allis, C. D. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90, 761–769 (2004).
  CAS PubMed PubMed Central Google Scholar
• Kuzmichev, A. & Reinberg, D. Role of histone deacetylase complexes in the regulation of chromatin metabolism. Curr. Top. Microbiol. Immunol. 254, 35–58 (2001).
  CAS PubMed Google Scholar
• Ushijima, T. Detection and interpretation of altered methylation patterns in cancer cells. Nature Rev. Cancer 5, 223–231 (2005).
  CAS Google Scholar
• Akama, T. O. et al. Restriction landmark genomic scanning (RLGS-M)-based genome-wide scanning of mouse liver tumors for alterations in DNA methylation status. Cancer Res. 57, 3294–3299 (1997).
  CAS PubMed Google Scholar
• Costello, J. F. et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet. 24, 132–138 (2000).
  CAS PubMed Google Scholar
• Yu, L. et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genet. 37, 265–274 (2005).
  CAS PubMed Google Scholar
• Huang, T. H., Perry, M. R. & Laux, D. E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8, 459–470 (1999).
  CAS PubMed Google Scholar
• Shi, H. et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 63, 2164–2171 (2003).
  CAS PubMed Google Scholar
• Salem, C. E. et al. PAX6 methylation and ectopic expression in human tumor cells. Int. J. Cancer 87, 179–185 (2000).
  CAS PubMed Google Scholar
• Suzuki, H. et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet. 31, 141–149 (2002).
  CAS PubMed Google Scholar
• Yamashita, K. et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485–495 (2002).
  CAS PubMed Google Scholar
• Toyota, M. et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59, 2307–2312 (1999).
  CAS PubMed Google Scholar
• Herman, J. G. et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95, 6870–6875 (1998).
  CAS PubMed PubMed Central Google Scholar
• Bachman, K. E. et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3, 89–95 (2003).
  CAS PubMed Google Scholar
• Myohanen, S. K., Baylin, S. B. & Herman, J. G. Hypermethylation can selectively silence individual p16 ink4A alleles in neoplasia. Cancer Res. 58, 591–593 (1998).
  CAS PubMed Google Scholar
• Parsons, R. et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55, 5548–5550 (1995).
  CAS PubMed Google Scholar
• Morin, P. J. et al. Activation of β-catenin–Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787–1790 (1997).
  CAS PubMed Google Scholar
• Akiyama, Y. et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 23, 8429–8439 (2003).
  CAS PubMed PubMed Central Google Scholar
• Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genet. 36, 417–422 (2004). Demonstrates that epigenetic loss of SFRP function occurs early in colorectal cancer progression, and that restoration of SFRP function in colorectal cancer cells attenuates Wnt signalling, even in the presence of downstream mutations.
  CAS PubMed Google Scholar
• Rhee, I. et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552–556 (2002).
  CAS PubMed Google Scholar
• Bachman, K. E. et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59, 798–802 (1999).
  CAS PubMed Google Scholar
• Gao, X., Sedgwick, T., Shi, Y. B. & Evans, T. Distinct functions are implicated for the GATA-4, -5, and-6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol. Cell. Biol. 18, 2901–2911 (1998).
  CAS PubMed PubMed Central Google Scholar
• Al-azzeh, E. et al. Gastroprotective peptide trefoil factor family 2 gene is activated by upstream stimulating factor but not by c-Myc in gastrointestinal cancer cells. Gut 51, 685–690 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bossenmeyer-Pourie, C. et al. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1–S phase transition and reducing apoptosis. J. Cell Biol. 157, 761–770 (2002).
  CAS PubMed PubMed Central Google Scholar
• Wright, N. A., Hoffmann, W., Otto, W. R., Rio, M. C. & Thim, L. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett. 408, 121–123 (1997).
  CAS PubMed Google Scholar
• Issa, J. P. CpG island methylator phenotype in cancer. Nature Rev. Cancer 4, 988–993 (2004). Reviews the concept of a DNA hyper-methylated phenotype.
  CAS Google Scholar
• Yamada, Y. et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl Acad. Sci. USA 102, 13580–13585 (2005).
  CAS PubMed PubMed Central Google Scholar
• Cui, H. et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753–1755 (2003).
  CAS PubMed Google Scholar
• Sakatani, T. et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307, 1976–1978 (2005).
  CAS PubMed Google Scholar
• Holm, T. M. et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8, 275–285 (2005).
  CAS PubMed Google Scholar
• Belinsky, S. A. et al. Aberrant methylation of p16 INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891–11896 (1998).
  CAS PubMed PubMed Central Google Scholar
• Nuovo, G. J., Plaia, T. W., Belinsky, S. A., Baylin, S. B. & Herman, J. G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96, 12754–12759 (1999).
  CAS PubMed PubMed Central Google Scholar
• Swafford, D. S. et al. Frequent aberrant methylation of p16 INK4a in primary rat lung tumors. Mol. Cell. Biol. 17, 1366–1374 (1997).
  CAS PubMed PubMed Central Google Scholar
• Lee, W. H. et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 11733–11737 (1994).
  CAS PubMed PubMed Central Google Scholar
• Holst, C. R. et al. Methylation of p16 INK4a promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63, 1596–1601 (2003).
  CAS PubMed Google Scholar
• Romanov, S. R. et al. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633–637 (2001).
  CAS PubMed Google Scholar
• Kiyono, T. et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88 (1998).
  CAS PubMed Google Scholar
• Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B. & Herman, J. G. Inactivation of the DNA repair gene _O_6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59, 793–797 (1999).
  CAS PubMed Google Scholar
• Esteller, M. et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60, 4366–4371 (2000).
  CAS PubMed Google Scholar
• Nelson, W. G., De Marzo, A. M. & Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366–381 (2003).
  CAS PubMed Google Scholar
• Wong, D. J., Foster, S. A., Galloway, D. A. & Reid, B. J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol. Cell. Biol. 19, 5642–5651 (1999).
  CAS PubMed PubMed Central Google Scholar
• Bronner, C. E. et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368, 258–261 (1994).
  CAS PubMed Google Scholar
• Kane, M. F. et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57, 808–811 (1997).
  CAS PubMed Google Scholar
• Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332–339 (1999).
  CAS PubMed Google Scholar
• Esteller, M. et al. Promoter hypermethylation of the DNA repair gene _O_6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 61, 4689–4692 (2001).
  CAS PubMed Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes — the Achilles heal of cancer. Science 297, 63–64 (2002).
  CAS PubMed Google Scholar
• Gregorieff, A. & Clevers, H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 19, 877–890 (2005).
  CAS PubMed Google Scholar
• Kinzler, K. W. & Vogelstein, B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761–763 (1997).
  CAS PubMed Google Scholar
• Weinstein, I. B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857–864 (2000).
  CAS PubMed Google Scholar
• Jen, J. et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54, 5523–5526 (1994).
  CAS PubMed Google Scholar
• DeAngelo, A. B., Geter, D. R., Rosenberg, D. W., Crary, C. K. & George, M. H. The induction of aberrant crypt foci (ACF) in the colons of rats by trihalomethanes administered in the drinking water. Cancer Lett. 187, 25–31 (2002).
  CAS PubMed Google Scholar
• Hao, X. P., Pretlow, T. G., Rao, J. S. & Pretlow, T. P. β-Catenin expression is altered in human colonic aberrant crypt foci. Cancer Res. 61, 8085–8088 (2001).
  CAS PubMed Google Scholar
• Mori, H., Yamada, Y., Kuno, T. & Hirose, Y. Aberrant crypt foci and β-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat. Res. 566, 191–208 (2004).
  CAS PubMed Google Scholar
• Papanikolaou, A., Wang, Q. S., Delker, D. A. & Rosenberg, D. W. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 130, 29–34 (1998).
  CAS PubMed Google Scholar
• Papanikolaou, A., Wang, Q. S., Papanikolaou, D., Whiteley, H. E. & Rosenberg, D. W. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21, 1567–1572 (2000).
  CAS PubMed Google Scholar
• Siu, I. M. et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res. 59, 63–66 (1999).
  CAS PubMed Google Scholar
• Yuan, P., Sun, M. H., Zhang, J. S., Zhu, X. Z. & Shi, D. R. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J. Gastroenterol. 7, 352–356 (2001).
  CAS PubMed PubMed Central Google Scholar
• Finch, P. W. et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl Acad. Sci. USA 94, 6770–6775 (1997).
  CAS PubMed PubMed Central Google Scholar
• Melkonyan, H. S. et al. SARPs: a family of secreted apoptosis-related proteins. Proc. Natl Acad. Sci. USA 94, 13636–13641 (1997).
  CAS PubMed PubMed Central Google Scholar
• Rattner, A. et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl Acad. Sci. USA 94, 2859–2863 (1997).
  CAS PubMed PubMed Central Google Scholar
• Taketo, M. M. Shutting down Wnt signal-activated cancer. Nature Genet. 36, 320–322 (2004).
  CAS PubMed Google Scholar
• Wales, M. M. et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med. 1, 570–577 (1995).
  CAS PubMed Google Scholar
• Guerardel, C. et al. Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J. Biol. Chem. 276, 3078–3089 (2001).
  CAS PubMed Google Scholar
• Fujii, H. et al. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 16, 2159–2164 (1998).
  CAS PubMed Google Scholar
• Carter, M. G. et al. Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller–Dieker syndrome. Hum. Mol. Genet. 9, 413–419 (2000).
  CAS PubMed Google Scholar
• Chen, W. Y. et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nature Genet. 33, 197–202 (2003).
  CAS PubMed Google Scholar
• Chen, W. et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6, 387–398 (2004).
  CAS PubMed Google Scholar
• Chen W. et al. Tumor suppressor HIC1 directly regulates SIRT1 and modulates p53-dependent apoptotic DNA damage responses. Cell 123, 437–448 (2005). Reports that the silencing of HIC1 in tumorigenesis might activate a network of events that lead to partial downregulation of p53 function and then to mutations in p53.
  CAS PubMed Google Scholar
• Frye, R. A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260, 273–279 (1999).
  CAS PubMed Google Scholar
• Vaziri, H. et al. hSIR2 SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107, 149–159 (2001).
  CAS PubMed Google Scholar
• Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383–2396 (2002).
  CAS PubMed PubMed Central Google Scholar
• Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137–148 (2001).
  CAS PubMed Google Scholar
• Hu, M. et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genet. 37, 899–905 (2005).
  CAS PubMed Google Scholar
• Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
  CAS PubMed Google Scholar
• Tlsty, T. D. Stromal cells can contribute oncogenic signals. Semin. Cancer Biol. 11, 97–104 (2001).
  CAS PubMed Google Scholar
• Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
  CAS PubMed Google Scholar
• Issa, J. P., Kantarjian, H. M. & Kirkpatrick, P. Azacitidine. Nature Rev. Drug Discov. 4, 275–276 (2005).
  CAS Google Scholar
• Peters, A. H. et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol. Cell 12, 1577–1589 (2003).
  CAS PubMed Google Scholar
• Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
  CAS PubMed Google Scholar
• Kouzarides, T. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 12, 198–209 (2002).
  CAS PubMed Google Scholar
• Lund, A. H. & van Lohuizen, M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16, 239–246 (2004).
  CAS PubMed Google Scholar
• Gasser, S. M. Positions of potential: nuclear organization and gene expression. Cell 104, 639–642 (2001).
  CAS PubMed Google Scholar
• Levine, S. S., King, I. F. & Kingston, R. E. Division of labor in polycomb group repression. Trends Biochem. Sci. 29, 478–485 (2004).
  CAS PubMed Google Scholar
• Ringrose, L. & Paro, R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu. Rev. Genet. 38, 413–443 (2004).
  CAS PubMed Google Scholar
• Valk-Lingbeek, M. E., Bruggeman, S. W. & van Lohuizen, M. Stem cells and cancer; the polycomb connection. Cell 118, 409–418 (2004).
  CAS PubMed Google Scholar
• Kuzmichev, A. et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl Acad. Sci. USA 102, 1859–1864 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315–2335 (2004).
  CAS PubMed Google Scholar
• Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629 (2002).
  CAS PubMed Google Scholar
• Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606–11611 (2003).
  CAS PubMed PubMed Central Google Scholar
• Kirmizis, A., Bartley, S. M. & Farnham, P. J. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol. Cancer Ther. 2, 113–121 (2003).
  CAS PubMed Google Scholar
• Lessard, J. et al. Functional antagonism of the Polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 13, 2691–2703 (1999).
  CAS PubMed PubMed Central Google Scholar
• Selker, E. U., Jensen, B. C. & Richardson, G. A. A portable signal causing faithful DNA methylation de novo in Neurospora crassa. Science 238, 48–53 (1987).
  CAS PubMed Google Scholar
• Tamaru, H. & Selker, E. U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414, 277–283 (2001).
  CAS PubMed Google Scholar
• Tamaru, H. & Selker, E. U. Synthesis of signals for de novo DNA methylation in Neurospora crassa. Mol. Cell. Biol. 23, 2379–2394 (2003).
  CAS PubMed PubMed Central Google Scholar
• Bell, M. V. et al. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell 64, 861–866 (1991).
  CAS PubMed Google Scholar
• Jackson, J. P., Lindroth, A. M., Cao, X. & Jacobsen, S. E. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 416, 556–560 (2002).
  CAS PubMed Google Scholar
• Johnson, L., Cao, X. & Jacobsen, S. Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation. Curr. Biol. 12, 1360–1367 (2002).
  CAS PubMed Google Scholar
• Cao, R. & Zhang, Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155–164 (2004).
  CAS PubMed Google Scholar
• Plath, K. et al. Role of histone H3 lysine 27 methylation in X inactivation. Science 300, 131–135 (2003).
  CAS PubMed Google Scholar
• Ayyanathan, K. et al. Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev. 17, 1855–1869 (2003). A model of the evolution of the abnormal heritable transcriptional gene silencing that occurs during tumour progression.
  CAS PubMed PubMed Central Google Scholar
• Fahrner, J. A. & Baylin, S. B. Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev. 17, 1805–1812 (2003).
  CAS PubMed Google Scholar
• Fahrner, J. A., Eguchi, S., Herman, J. G. & Baylin, S. B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62, 7213–7218 (2002).
  CAS PubMed Google Scholar
• Kondo, Y., Shen, L. & Issa, J. P. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol. 23, 206–215 (2003).
  CAS PubMed PubMed Central Google Scholar
• Nguyen, C. T. et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62, 6456–6461 (2002).
  CAS PubMed Google Scholar
• Ghoshal, K. et al. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol. Cell. Biol. 22, 8302–8319 (2002).
  CAS PubMed PubMed Central Google Scholar
• Koizume, S., Tachibana, K., Sekiya, T., Hirohashi, S. & Shiraishi, M. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res. 30, 4770–4780 (2002).
  CAS PubMed PubMed Central Google Scholar
• Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103–107 (1999).
  CAS PubMed Google Scholar
• Laird, P. W. The power and the promise of DNA methylation markers. Nature Rev. Cancer 3, 253–266 (2003).
  CAS Google Scholar